{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:17:46Z","timestamp":1791573466061,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.mayocp.2023.08.029","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T09:59:36Z","timestamp":1704189576000},"page":"26-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9547-887X","authenticated-orcid":false,"given":"Juan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1586","authenticated-orcid":false,"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.mayocp.2023.08.029_bib1","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9865","key":"10.1016\/j.mayocp.2023.08.029_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"10093","key":"10.1016\/j.mayocp.2023.08.029_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2023.08.029_bib6","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1377\/hlthaff.25.6.1637","article-title":"Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending","volume":"25","author":"Kesselheim","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.mayocp.2023.08.029_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108780","article-title":"A\u00a0randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz\u00ae in Chinese healthy subjects","volume":"109","author":"Xu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"10.1016\/j.mayocp.2023.08.029_bib10","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1007\/s10067-022-06205-z","article-title":"Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India","volume":"41","author":"Phatak","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.mayocp.2023.08.029_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40273-020-00961-z","article-title":"Cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis in China","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.mayocp.2023.08.029_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/1756-185X.13244","article-title":"Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: patient-reported outcomes from a Phase 3 randomized controlled trial","volume":"21","author":"Li","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.mayocp.2023.08.029_bib13","article-title":"Approval of Tofacitinib Citrate Tablets for rheumatoid arthritis from China Food and Drug Administration [in Chinese]","year":"2020","journal-title":"National Medical Products Administration"},{"key":"10.1016\/j.mayocp.2023.08.029_bib14","article-title":"Drug instruction of Tofacitinib Citrate Tablets [in Chinese]","year":"2020","journal-title":"Center for Drug Evaluation"},{"issue":"3","key":"10.1016\/j.mayocp.2023.08.029_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40744-022-00441-0","article-title":"Towards a better implementation of treat-to-target strategy in rheumatoid arthritis: a comparison of two real-world cohorts","volume":"9","author":"Huang","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.mayocp.2023.08.029_bib16","first-page":"2485","article-title":"Musculoskeletal ultrasound including definitions for ultrasonographic pathology","volume":"32","author":"Wakefield","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2023.08.029_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.10877","article-title":"Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis","volume":"48","author":"Szkudlarek","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib19","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs","volume":"25","author":"Borgheini","year":"2003","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2023.08.029_bib20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-020-01296-x","article-title":"Are generic drugs used in cardiology as effective and safe as their brand-name counterparts? a systematic review and meta-analysis","volume":"80","author":"Leclerc","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.mayocp.2023.08.029_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.33312","article-title":"Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity","volume":"64","author":"Foltz","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocp.2023.08.029_bib22","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/rheumatology\/keaa004","article-title":"Prospective\u00a0observational study to evaluate the use of musculoskeletal ultrasonography in rheumatoid arthritis management: the ECHO study","volume":"59","author":"Stein","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.mayocp.2023.08.029_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients\u00a0with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2023.08.029_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases","volume":"77","author":"Kay","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.mayocp.2023.08.029_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000757","article-title":"Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study","volume":"4","author":"Matucci-Cerinic","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.mayocp.2023.08.029_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.980832","article-title":"Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: a cohort study","volume":"13","author":"Carballo","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2023.08.029_bib27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bcp.13170","article-title":"GP2015, a proposed etanercept biosimilar: pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes","volume":"83","author":"von Richter","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.mayocp.2023.08.029_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2023.08.029_bib29","first-page":"777","article-title":"Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan","volume":"22","author":"Chen","year":"2019","journal-title":"J\u00a0Med Econ"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623004482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619623004482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T11:56:16Z","timestamp":1704455776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619623004482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0025619623004482"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.08.029","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Clinical Equivalence of Generic and Branded Tofacitinib: A Prospective Longitudinal Cohort Study in Patients With Rheumatoid Arthritis","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2023.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}